在体探索骨质细胞前体抑制,以防止在停止使用登苏马布后的快速骨损失
Young Kwan Kim1,2, Yoshitaka Kameo3, Sakae Tanaka2
1Department of Biosystems Science, Institute for Life and Medical Sciences, Kyoto University, Sakyo, Kyoto, Japan.
NPJ systems biology and applications
|February 18, 2026
概括
停止治疗骨质疏松症的德诺苏马布会导致骨质损失. 使用骨质细胞前体抑制剂 (OCPI) 的新策略通过诱导亡,保持骨质量来防止这种反弹.
科学领域:
- 骨生物学和药理学 骨生物学和药理学
- 骨质疏松症的治疗方法
- 药物开发战略 药物开发策略
背景情况:
- 德诺苏马布通过减少骨再吸收来有效治疗骨质疏松症.
- 停用德诺苏马布可以导致由于骨质细胞前体活性增加而导致骨质损失反弹现象.
- 目前的治疗方法可能无法完全解决这种反弹效应.
研究的目的:
- 提出和评估一种新的治疗策略,以防止denosumab诱导的反弹骨损失.
- 为了研究未开发的骨质细胞前体抑制剂 (OCPI) 预防反弹骨损失的疗效.
- 为了比较OCPI与alendronate in silico的影响.
主要方法:
- 在体实验中模拟denosumab治疗,然后进行OCPI或alendronate.
- 骨质细胞前体积累和活动的建模.
- 对骨细胞活动和骨形成的影响的评估.
主要成果:
- 停止服用德诺苏马布导致了由积累的前体驱动的过度骨质细胞活动.
- 切换到OCPI以骨质细胞占主导地位的方式抑制了骨质再吸收,与alendronate不同.
- 联合使用OCPI和denosumab可以防止反弹性骨损失,并保留denosumab诱导的骨形成.
结论:
- 使用OCPI诱导骨质细胞前体亡是一种可行的策略,可以防止在停止使用denosumab后的反弹骨损失.
- 与阿伦德罗纳酸相比,OCPI表现出一种不同的作用机制,向骨质细胞前体而不会直接影响骨质细胞.
- 在模型提供了OCPI的概念证明,可能加速开发新的骨质疏松症治疗方法.
相关概念视频
01:31Osteoclasts in Bone Remodeling
4.3K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.3K
01:40Bone Remodeling
40.6K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.6K
01:29Bone Disorders
5.6K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.6K